Biocon Biologics secures market entry date for Yesafili in US

YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions

Bayer announces positive topline resukts for Aflibercept 8 mg in phase III study

Demonstrates vision gains with extended treatment intervals in retinal vein occlusion

Long-term efficacy and safety profile of Eylea 8 mg with extended dosing intervals in diabetic macular edema confirmed at three years

Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years

Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype

EC approves Ordspono for the treatment of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma

Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission

Biocon Biologics secures Canada market entry date for YESAFILI

This agreement paves the way for the introduction of YESAFILI into the Canadian market

Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial

Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

Dupixent is now approved in India for the treatment of adults with moderate-to-severe atopic dermatitis

Top 20 global biopharma companies report 3.4% fall in market cap in Q1 2023: GlobalData

Bayer reported the highest market capitalization growth of 23.1% during Q1 2023

Biogen appoints Christopher Viehbacher as President and CEO

Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies